Asthma: No Clear Winners in Combination Treatment in Blacks Asthma: No Clear Winners in Combination Treatment in Blacks

A randomized trial showed no benefit to long-acting beta-agonists over tiotropium in combination with inhaled corticosteroid for improving outcomes in black adults with asthma. Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Internal Medicine News Source Type: news

Related Links:

We report the development of eosinophilic polyangiitis granulomatosis (EGPA) in a young girl being treated for both atopic dermatitis, diagnosed at 1 year of age, and bronchial asthma, diagnosed at 4 years of age. Her eruption did not result in lichenification and was not fully responsive to corticosteroid ointment. Asthma lightened by treatment of inhalational steroids. Hypereosinophilia was detected at 5 years of age, at least 20% of white blood cells, and 44% at 8 years of age. At 10 years of age, she was diagnosed with anti-neutrophil cytoplasmic antibody-negative EGPA. The diagnosis was based on findings of eosinophil...
Source: Arerugi - Category: Allergy & Immunology Authors: Tags: Arerugi Source Type: research
Clinical management of asthma and chronic obstructive pulmonary disease (COPD) has primarily relied on the use of beta 2 adrenergic receptor agonists (bronchodilators) and corticosteroids, and more recently, monoclonal antibody therapies (biologics) targeting specific cytokines and their functions. Although these approaches provide relief from exacerbations, questions remain on their long-term efficacy and safety. Furthermore, current therapeutics do not address progressive airway remodeling (AR), a key pathological feature of severe obstructive lung disease. Strikingly, agonists of the bitter taste receptors (TAS2Rs) deli...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
AbstractThe use of biologic agents as therapies for atopic diseases such as asthma and atopic dermatitis has increased greatly in recent years. The biological agents used to treat atopic diseases are for the most part monoclonal antibodies that suppress the immune response and reduce inflammation by targeting particular cytokines or other molecules involved in Th1, Th2, or Th17 immune reactions. Various side effects and rare complications have been reported from these agents. In this review, we discuss mechanisms of various adverse effects for the biologic agents currently in use or in development for atopic and inflammato...
Source: Clinical Reviews in Allergy and Immunology - Category: Allergy & Immunology Source Type: research
Conclusions: Asthma and COPD patients using DuoResp Spiromax reported moderate-to-high medication adherence, were very satisfied with their inhaler and found it easy to use. PMID: 31293211 [PubMed - as supplied by publisher]
Source: Journal of Asthma - Category: Respiratory Medicine Tags: J Asthma Source Type: research
Source: FDA Drug Safety Podcasts - Category: Drugs & Pharmacology Authors: Source Type: podcasts
Condition:   Acute Asthma Interventions:   Drug: Budesonide;   Drug: normal saline Sponsor:   University of Monastir Recruiting
Source: - Category: Research Source Type: clinical trials
In contrast to asthma, the inflammatory response induced by human respiratory syncytial virus (RSV) infection is refractory to glucocorticoid treatment1,2 for reasons that are not clear. Reduced corticosteroid responsiveness at the cellular and clinical level is associated with reduced numbers of glucocorticoid receptor (GRs).3,4 We previously showed that RSV infection downregulated GR mRNA and protein levels in RSV-infected A549  cells and in BALB/c mice.5 Other studies showed that downregulated GR levels were associated with an increase in the microRNAs (miRNAs) miR-124-3p, miR-142-3p, and miR-29a.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Tags: Letter to the Editor Source Type: research
We read with interest the study by Cardet et  al,1 which showed that 38% of asthmatic patients receiving an inhaled corticosteroid (ICS) and a long-acting β-agonist (LABA; ie, fluticasone/salmeterol) experienced loss of bronchoprotection. We believe that their results need to be interpreted in light of the potential interaction between the L ABA moiety and the arginine/glycine genotype at position 16 (Arg16Gly) of the β2-adrenoceptor. For example, a post hoc genotype-stratified pooled analysis of 152 patients from randomized placebo-controlled trials showed that the degree of protection after chronic dosing ...
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Tags: Correspondence Source Type: research
The European Respiratory Biologics Forum gathered participants from 21 countries in Madrid, Spain, to discuss the management and treatment of severe asthma in the era of biologics. The current insights on the pathophysiology of severe asthma were discussed, as well as the role of respiratory biologics in clinical practice and strategies for eliminating chronic use of oral corticosteroids. The participants also highlighted the key challenges in identifying patients with severe asthma based on phenotypes, biomarkers and treatable traits, and the existing problems in patient referral to specialist care. The monitoring of trea...
Source: European Respiratory Review - Category: Respiratory Medicine Authors: Tags: Asthma and allergy Review Source Type: research
CONCLUSIONS: Clearly, aspirin desensitization and treatment are beneficial for AERD patients, with a reduction of nasal symptoms, improvements in asthma control and decrease of daily corticosteroid use, without fatal adverse events. However, long-term side effects of aspirin desensitization and optimal dosage of aspirin merit further investigation. PMID: 31283521 [PubMed - as supplied by publisher]
Source: Journal of Investigational Allergology and Clinical Immunology - Category: Allergy & Immunology Authors: Tags: J Investig Allergol Clin Immunol Source Type: research
More News: Asthma | Corticosteroid Therapy | Health | Internal Medicine | Spiriva | Tiotropium